Results 121 to 130 of about 19,412 (203)

Effect of diosmectite on the pharmacokinetics of osimertinib in rats

Scientific Reports
Diosmectite is commonly used in clinical practice to manage osimertinib-induced diarrhea, but its impact on osimertinib absorption remains unclear. Eighteen male Sprague–Dawley rats were randomly assigned to three groups (n=6/group): control (osimertinib
Guangzhao He, Jing Wu, Yanzhi Bi, Cong Fu, Yanchu Yang, Yuanyuan Zu, Dan Huo, Jingping Yu   +7 more
doaj   +1 more source

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study

, 2019
Satoshi Igawa,1 Taihei Ono,1 Masashi Kasajima,1 Mikiko Ishihara,1 Yasuhiro Hiyoshi,1 Seiichiro Kusuhara,1 Noriko Nishinarita,1 Tomoya Fukui,1 Masaru Kubota,1 Jiichiro Sasaki,2 Mitsufuji Hisashi,3 Masanori Yokoba,4 Masato Katagiri,4 Katsuhiko ...
Sasaki J, Hisashi M, Ono T, Kusuhara S, Hiyoshi Y, Nishinarita N, Kubota M, Fukui T, Kasajima M, Igawa S, Ishihara M, Yokoba M, Katagiri M, Naoki K   +13 more
core  

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

, 2019
Viola W Zhu,1 Alexa B Schrock,2 Siraj M Ali,2 Sai-Hong Ignatius Ou1 1Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA; 2Clinical ...
Schrock AB, Ali SM, Zhu VW, Ou SI
core  

Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover

Non–small cell lung cancer (NSCLC) is a common cause of cancer-related deaths worldwide, and its incidence has been increasing in recent years. While targeted therapies like osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor, have
Wei Li, Ruirui Wang, Jinzhuang Liao, Xinfang Yu, Qiang Wang   +4 more
core   +1 more source

A 51‐year‐old female presenting with headache and vision loss

Headache: The Journal of Head and Face Pain, Volume 66, Issue 8, Page 1928-1932, September 2026.
Laurel Ovrom, Zachary Pardieck, Randy Christopher Bowen, Neena R. Cherayil   +3 more
wiley   +1 more source

LUAD parental vs osimertinib-resistant

Gene expression data (FPKM) of three lung adenocarcinoma cell lines (PC-9, HCC827, and H1975) with osimertinib-resistance compared to their parental cell lines.
Jiaqi Liang (17730828)
core   +1 more source

Redefining early stage non–small cell lung cancer: The dawn of the risk‐adaptive and biologically precise era

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Clarissa Mathias, Fabio Ynoe Moraes
wiley   +1 more source

INSIGHT 2 : a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

: MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibitor,
Raskin, Jo, Morise, Masahire, Wu, Yi-Long, Dooms, Christophe, Tan, Daniel, Nadal, Ernest, Smit, Egbert F., Hin, How S., Zhu, Viola W., Karachaliou, Niki, Ellers-Lenz, Barbara, Holmberg, Kristina H., Schumacher, Karl M., Adrian, Svenja, Brutlach, Sabine, Tho, Lye M., Le, Xiuning, Mazieres, Julien   +17 more
core  

A fungal-derived benzothiazole derivative overcomes osimertinib resistance in NSCLC by targeting SCD1. [PDF]

Nat Prod Bioprospect
Li B, Ke Y, Zhu J, Zhang W, Yang M, Li Z, Chen M, Liu Z, Liu J, Deng Q, Zhang P, Lei X.   +11 more
europepmc   +1 more source

Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer. [PDF]

Front Oncol
Zhang H, Chen C, Wu D, Li W, Gong H, Liu C, Wu H, Zhang Q, Liu H, Chen J, Li Y.   +10 more
europepmc   +1 more source